

Special Issue

Genetic Diagnosis and Treatment of Duchenne Muscular Dystrophy

Message from the Guest Editor

Duchenne muscular dystrophy (DMD) is one of the most common forms of muscular dystrophy, caused by mutations in the *DMD* gene encoding dystrophin protein, the deficiency or absence of which leads to progressive muscle weakness, cardiac and respiratory failure, and premature death. The *DMD* gene is the largest gene in the human genome with a highly diverse mutational profile that includes single and multiple exon duplications and deletions, as well as single-point and frameshift mutations that disrupt the dystrophin open reading frame. Over the past few decades, many therapeutic strategies have been developed and tested, some of which have received regulatory approval, and we expect that more will follow. This Special Issue seeks to highlight advances in basic, translational, and clinical research to understand DMD at the molecular and structural levels. We welcome original research articles and reviews that highlight the development of meaningful therapies for DMD using cutting-edge technologies, biomarkers, and methods that standardize the functional outcome measures needed to assess therapeutic efficacy. Original research articles and reviews will be considered for publication.

Guest Editor

Dr. Liubov V. Gushchina

The Center for Gene Therapy, Nationwide Children's Hospital,
Columbus, OH, USA

Deadline for manuscript submissions

25 May 2026

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/245116

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))